Drug intelligence / Profile preview

NNC0165-1562 + semaglutide

Development stage: Unknown
Lead developer: Novo Nordisk
Modality: Peptides
Administration: Subcutaneous

Overview

NNC0165-1562 + semaglutide is a **combination therapy** investigated for weight loss and metabolic diseases. **NNC0165-1562** is a peptide YY (PYY) analog, while **semaglutide** is a glucagon-like peptide 1 receptor (GLP-1R) agonist. This combination is hypothesized to have synergistic effects on appetite suppression and weight reduction. Both components are administered via once-weekly subcutaneous injection. The combination is developed by Novo Nordisk and has been studied in early phase trials in people with obesity or overweight to assess safety, pharmacokinetics, and efficacy.

Targets

NPY2R (Neuropeptide Y receptor subtype 2)GLP1R (GLP-1R)

Beyond the preview

Go deeper on NNC0165-1562 + semaglutide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NNC0165-1562 + semaglutide.

Explore the full profile